MYOVANT SCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • October 26th, 2021 • Myovant Sciences Ltd. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is hereby made between Myovant Sciences, Inc. (the “Company”) and Uneek Mehra (the “Executive”) (collectively, the “Parties”). This Agreement shall become effective on August 12, 2021 (the “Effective Date”).
SEPARATION AGREEMENT AND GENERAL RELEASESeparation Agreement • October 26th, 2021 • Myovant Sciences Ltd. • Pharmaceutical preparations • California
This Separation Agreement and General Release (this “Agreement”) is hereby entered into as of August 11, 2021, by and between Frank Karbe, an individual (the “Employee”), and Myovant Sciences, Inc. (the “Company”), on behalf of itself, and its direct and indirect parents, subsidiaries and affiliated entities (collectively, the “Company Group”).
CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Collaboration License Agreement • October 26th, 2021 • Myovant Sciences Ltd. • Pharmaceutical preparations • New York
This side letter agreement (the “Side Letter Agreement”) relates to the Myovant/Pfizer Agreement, under which Myovant and Pfizer have agreed for Pfizer to have an exclusive option to obtain exclusive commercialization and promotion rights and related development rights for the Oncology Product(s) in the Oncology Field in the Pfizer Territory (each as defined therein), among other activities, in accordance with the terms of the Myovant/Pfizer Agreement. The Parties entered into a prior Side Letter Agreement, dated May 4, 2021, extending the time period within which Pfizer may exercise such exclusive option under Section 10.5 of the Agreement. The Parties now wish to enter into this Side Letter Agreement to further extend the time period within which Pfizer may exercise such exclusive option under Section 10.5 of the Agreement.
